Concert Pharmaceuticals IncNASDAQ:CNCE
- LAST PRICE6.2700
- TODAY'S CHANGE (%)0.1400 (2.2838%)
- Bid / Lots6.2500/ 8
- Ask / Lots6.2700/ 2
- Open / Previous Close6.2900 / 6.1300
- Day Range
- 52 Week Range
- Volume119,223
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | CNCE |
|---|---|---|
| 09:32 ET | 13579 | 6.4113 |
| 09:34 ET | 5034 | 6.435 |
| 09:36 ET | 3553 | 6.375 |
| 09:38 ET | 4409 | 6.4345 |
| 09:39 ET | 13108 | 6.395 |
| 09:41 ET | 5566 | 6.38 |
| 09:43 ET | 12066 | 6.38 |
| 09:45 ET | 3969 | 6.345 |
| 09:48 ET | 6242 | 6.31 |
| 09:50 ET | 996 | 6.31 |
| 09:52 ET | 3804 | 6.33 |
| 09:54 ET | 5050 | 6.3285 |
| 09:56 ET | 4672 | 6.2774 |
| 09:57 ET | 6765 | 6.305 |
| 09:59 ET | 450 | 6.305 |
| 10:01 ET | 600 | 6.3 |
| 10:03 ET | 2501 | 6.26 |
| 10:06 ET | 100 | 6.24 |
| 10:08 ET | 2473 | 6.24 |
| 10:10 ET | 1090 | 6.25 |
| 10:14 ET | 300 | 6.25 |
| 10:15 ET | 941 | 6.29 |
| 10:17 ET | 4035 | 6.27 |
Aug 4, 2022
BRIEF-Concert Pharmaceuticals Reports Second Quarter 2022 Financial Results, from 7:29AM ET on Thursday Aug 04, 2022 by Thomson Reuters
7:29AM ET on Thursday Aug 04, 2022 by Thomson Reuters-- Earnings Flash (CNCE) CONCERT PHARMACEUTICALS Reports Q2 Revenue $21,000, from 7:00AM ET on Thursday Aug 04, 2022 by MT Newswires
7:00AM ET on Thursday Aug 04, 2022 by MT NewswiresConcert Pharmaceuticals Reports Second Quarter 2022 Financial Results, from 7:00AM ET on Thursday Aug 04, 2022 by Business Wire
7:00AM ET on Thursday Aug 04, 2022 by Business Wire
Aug 1, 2022
Sector Update: Health Care Stocks Retreat Fractionally in Early Afternoon Trading, from 12:48PM ET on Monday Aug 01, 2022 by MT Newswires
12:48PM ET on Monday Aug 01, 2022 by MT NewswiresConcert Pharmaceuticals Reports Positive Topline Results in Hair Loss Trial; Shares Soar, from 10:35AM ET on Monday Aug 01, 2022 by MT Newswires
10:35AM ET on Monday Aug 01, 2022 by MT Newswires
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Concert Pharmaceuticals Inc | 284.8M | -2.4x | --- |
Poseida Therapeutics Inc | 257.8M | -1.7x | --- |
Voyager Therapeutics Inc | 266.5M | -3.5x | --- |
Epizyme Inc | 255.9M | -0.7x | --- |
Alpine Immune Sciences Inc | 269.9M | -5.1x | --- |
Aveo Pharmaceuticals Inc | 268.2M | -6.7x | --- |
Company Information
Concert Pharmaceuticals, Inc. is a late-stage clinical biopharmaceutical company. The Company is focused on developing CTP-543, a Janus Kinase 1 and Janus Kinase 2 (JAK 1/2) inhibitor that discovered through deuterated chemical entity Platform (DCE platform). The Company is evaluating CTP-543 in a Phase III clinical program for the treatment of alopecia areata, a serious autoimmune dermatological condition. Through DCE Platform, the Company has discovered and developed novel drugs designed to have properties, including enhanced clinical safety, tolerability or efficacy based on compounds. DCE technology has range of potential across numerous therapeutic areas, including for chronic diseases for which medicines are continually used by patients. The Company is assessing earlier-stage pipeline candidates as potential development candidates, including a once-daily, modified release formulation of CTP-543.
Contact Information
- Headquarters
- Suite 500, 99 Hayden AvenueLEXINGTON, MA, United States 02421
- Phone
- 781-860-0045
- Fax
- 302-636-5454
Executives
- Independent Chairman of the Board, Co-founder
- Richard Aldrich
- President, Chief Executive Officer, Co-Founder, Director
- Roger Tung
- Chief Financial Officer
- Marc Becker
- Chief Operating Officer
- Nancy Stuart
- Chief Development Officer
- James Cassella
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $284.8M |
|---|---|
Revenue (TTM) | $32.6M |
Shares Outstanding | 46.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.68 |
EPS | $-2.67 |
Book Value | $3.23 |
P/E Ratio | -2.4x |
Price/Sales (TTM) | 8.7 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -274.94% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
